# Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant

> **NCT02771197** · PHASE2 · COMPLETED · sponsor: **Northside Hospital, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Melphalan
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02771197
- **Lead sponsor:** Northside Hospital, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-28
- **Primary completion:** 2022-08-03
- **Final completion:** 2023-07-31
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02771197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02771197, "Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02771197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*